27711225|t|Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone
27711225|a|Benign human prostate tubule-initiating cells (TIC) and aggressive prostate cancer display common traits, including tolerance of low androgen levels, resistance to apoptosis, and microenvironment interactions that drive epithelial budding and outgrowth. TIC can be distinguished from epithelial and stromal cells that comprise prostate tissue via cell sorting based upon Epcam, CD44, and CD49f antigenic profiles. Fetal prostate epithelial cells (FC) possess a similar antigenic profile to adult TIC and are capable of inducing tubule formation. To identify the TIC niche in human prostate tissue, differential keratin (KRT) expression was evaluated. Gene expression data generated from Affymetrix Gene Chip human U133 Plus 2.0 array of sorted adult and fetal epithelial cells revealed KRT13 to be significantly enriched in FC and TIC compared to basal cells (BC) and luminal cells (LC) (p<0.001). Enriched KRT13 expression was confirmed by RT-PCR and cytospin immunostaining. Immunohistochemical analysis of KRT13 expression revealed rare KRT13+ epithelia throughout prostatic ducts / acini in adult tissue specimens and differentiated tubules in 24- week recombinant grafts, In contrast, abundant KRT13 expression was observed in developing ducts / acini in fetal prostate and cord-like structures composing 8- week recombinant grafts. Immunostaining of a prostate tissue microarray revealed KRT13+ tumor foci in approximately 9% of cases, and this subset displayed significantly shorter time to recurrence (p = 0.031), metastases (p = 0.032), and decreased overall survival (p = 0.004). Diagnostic prostate needle biopsies (PNBX) from untreated patients with concurrent bone metastases (clinical stage M1) displayed KRT13+ tumor foci, as did bone metastatic foci. The expression profile of KRT13 in benign fetal and adult prostate tissue and in recombinant grafts, as well as the frequency of KRT13 expression in primary and metastatic prostate cancer indicates that it may be a marker of a stem/progenitor-like cell state that is co-opted in aggressive tumor cells. KRT13 is enriched in benign stem-like cells that display androgen - resistance, apoptosis - resistance, and branching morphogenesis properties. Collectively our data demonstrate that KRT13 expression is associated with poor prognosis at multiple stages of disease progression and may represent an important biomarker of adverse outcome in patients with prostate cancer.
27711225	0	10	Keratin 13	T103	UMLS:C0010804
27711225	26	34	Prostate	T017	UMLS:C0033572
27711225	35	58	Tubule-Initiating Cells	T017	UMLS:C0007634
27711225	76	99	Primary Prostate Tumors	T038	UMLS:C0033578
27711225	105	116	Metastasize	T038	UMLS:C0027627
27711225	124	128	Bone	T017	UMLS:C0262950
27711225	136	141	human	T204	UMLS:C0086418
27711225	142	150	prostate	T017	UMLS:C0033572
27711225	151	174	tubule-initiating cells	T017	UMLS:C0007634
27711225	176	179	TIC	T017	UMLS:C0007634
27711225	196	211	prostate cancer	T038	UMLS:C0600139
27711225	258	277	low androgen levels	T033	UMLS:C3203518
27711225	293	302	apoptosis	T038	UMLS:C0162638
27711225	308	337	microenvironment interactions	T038	UMLS:C0007613
27711225	349	367	epithelial budding	T038	UMLS:C1155616
27711225	372	381	outgrowth	T038	UMLS:C0007595
27711225	383	386	TIC	T017	UMLS:C0007634
27711225	413	423	epithelial	T017	UMLS:C0014597
27711225	428	441	stromal cells	T017	UMLS:C0162597
27711225	456	471	prostate tissue	T017	UMLS:C0227964
27711225	476	488	cell sorting	T058	UMLS:C0007616
27711225	500	505	Epcam	T017	UMLS:C0812305
27711225	507	511	CD44	T017	UMLS:C1332712
27711225	517	522	CD49f	T017	UMLS:C1442491
27711225	543	574	Fetal prostate epithelial cells	T017	UMLS:C0014597
27711225	576	578	FC	T017	UMLS:C0014597
27711225	598	607	antigenic	T103	UMLS:C0003320
27711225	625	628	TIC	T017	UMLS:C0007634
27711225	657	673	tubule formation	T033	UMLS:C1718420
27711225	691	694	TIC	T017	UMLS:C0007634
27711225	704	709	human	T204	UMLS:C0086418
27711225	710	725	prostate tissue	T017	UMLS:C0227964
27711225	740	747	keratin	T103	UMLS:C0010804
27711225	749	752	KRT	T103	UMLS:C0010804
27711225	754	764	expression	T038	UMLS:C1171362
27711225	769	778	evaluated	T058	UMLS:C0220825
27711225	780	795	Gene expression	T038	UMLS:C0017262
27711225	816	862	Affymetrix Gene Chip human U133 Plus 2.0 array	T062	UMLS:C4284067
27711225	889	905	epithelial cells	T017	UMLS:C0014597
27711225	915	920	KRT13	T103	UMLS:C1673263
27711225	953	955	FC	T017	UMLS:C0014597
27711225	960	963	TIC	T017	UMLS:C0007634
27711225	976	987	basal cells	T017	UMLS:C0596155
27711225	989	991	BC	T017	UMLS:C0596155
27711225	997	1010	luminal cells	T017	UMLS:C0007634
27711225	1012	1014	LC	T017	UMLS:C0007634
27711225	1036	1041	KRT13	T103	UMLS:C1673263
27711225	1042	1052	expression	T038	UMLS:C1171362
27711225	1070	1076	RT-PCR	T062	UMLS:C0599161
27711225	1081	1104	cytospin immunostaining	T058	UMLS:C0016318
27711225	1138	1143	KRT13	T103	UMLS:C1673263
27711225	1144	1154	expression	T038	UMLS:C1171362
27711225	1169	1175	KRT13+	T103	UMLS:C1673263
27711225	1197	1212	prostatic ducts	T017	UMLS:C0227965
27711225	1215	1220	acini	T017	UMLS:C0229962
27711225	1230	1246	tissue specimens	T017	UMLS:C1292533
27711225	1266	1273	tubules	T017	UMLS:C3893601
27711225	1328	1333	KRT13	T103	UMLS:C1673263
27711225	1334	1344	expression	T038	UMLS:C1171362
27711225	1372	1377	ducts	T017	UMLS:C0227965
27711225	1380	1385	acini	T017	UMLS:C0229962
27711225	1389	1403	fetal prostate	T017	UMLS:C0033572
27711225	1408	1428	cord-like structures	T082	UMLS:C0678594
27711225	1487	1495	prostate	T017	UMLS:C0033572
27711225	1523	1535	KRT13+ tumor	T038	UMLS:C0027651
27711225	1536	1540	foci	T082	UMLS:C0205234
27711225	1580	1586	subset	T170	UMLS:C1515021
27711225	1651	1661	metastases	T038	UMLS:C0027627
27711225	1719	1754	Diagnostic prostate needle biopsies	T058	UMLS:C3867555
27711225	1756	1760	PNBX	T058	UMLS:C3867555
27711225	1767	1776	untreated	T033	UMLS:C0332155
27711225	1802	1817	bone metastases	T038	UMLS:C0153690
27711225	1819	1836	clinical stage M1	T033	UMLS:C0441971
27711225	1848	1854	KRT13+	T103	UMLS:C1673263
27711225	1855	1860	tumor	T038	UMLS:C0027651
27711225	1861	1865	foci	T082	UMLS:C0205234
27711225	1874	1878	bone	T017	UMLS:C0262950
27711225	1879	1889	metastatic	T038	UMLS:C0027627
27711225	1890	1894	foci	T082	UMLS:C0205234
27711225	1900	1918	expression profile	T033	UMLS:C3463810
27711225	1922	1927	KRT13	T103	UMLS:C1673263
27711225	1954	1969	prostate tissue	T017	UMLS:C0227964
27711225	2025	2030	KRT13	T103	UMLS:C1673263
27711225	2031	2041	expression	T038	UMLS:C1171362
27711225	2057	2083	metastatic prostate cancer	T038	UMLS:C0936223
27711225	2111	2117	marker	T201	UMLS:C0005516
27711225	2123	2143	stem/progenitor-like	T017	UMLS:C0038250
27711225	2144	2148	cell	T017	UMLS:C0007634
27711225	2192	2197	cells	T017	UMLS:C0007634
27711225	2199	2204	KRT13	T103	UMLS:C1673263
27711225	2227	2236	stem-like	T017	UMLS:C0038250
27711225	2237	2242	cells	T017	UMLS:C0007634
27711225	2256	2264	androgen	T103	UMLS:C0002844
27711225	2279	2288	apoptosis	T038	UMLS:C0162638
27711225	2307	2330	branching morphogenesis	T038	UMLS:C1622374
27711225	2382	2387	KRT13	T103	UMLS:C1673263
27711225	2388	2398	expression	T038	UMLS:C1171362
27711225	2423	2432	prognosis	T201	UMLS:C3854082
27711225	2455	2474	disease progression	T038	UMLS:C0242656
27711225	2506	2515	biomarker	T201	UMLS:C0005516
27711225	2552	2567	prostate cancer	T038	UMLS:C0600139